Together, the discordance between TMB-high, PD-L1, and HS classification, suggest that treatment opportunities in otherwise treatment-sensitive patients would be lost when using current pre-specified cutoffs of TMB and PD-L1 scoring to select patients for anti-PD1 treatment in a pan-cancer setting. The gene discussed is PDCD1; the disease is cancer.